Healthcare shares are lower in pre-market, while NPS
) is up about 4% in pre-market trade as it said the U.S. Food and
Drug Administration has accepted for review its supplemental new
drug application for Gattex for injection to treat short bowel
syndrome in adults who are dependent on parenteral support.
And, shares of Sinovac Biotech Ltd. (
) are up nearly 10% at $6.45 in pre-market after the China-based
biopharmaceutical company reported overnight a net income in Q3
2013 on increased sales, driven by the expanded capacity of SVA's
fully operational Changping filling and packaging line.
SVA said net income was $2.3 million, or $0.04 per diluted
share, compared to a net loss of $3 million, or $0.05 per diluted
share, in the same period last year. Sales totaled $22.1 million,
up 54.5% from $14.3 million in the prior-year quarter.
No analyst estimates were available for comparison.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.